English

Nomination committee in IRLAB appointed

Report this content

IRLAB announced today that in preparation for the annual general meeting 2020, the company’s three largest shareholders, or groups of shareholders, have appointed members of the nomination committee. The nomination committee consists of Bo Rydlinger, Daniel Johnsson and Clas Sonesson beside Anders Vedin, the chairman of the board. The nomination committee represents about 57 percent of shares and votes in the company.

According to the instruction for appointment of the nomination committee in IRLAB Therapeutics AB, resolved at the annual general meeting on April 25, 2019, the nomination committee shall, besides the chairman of the board, consist of representatives of the three largest shareholders, or groups of shareholders, as per August 31.

As the three largest shareholders or groups of shareholders now have appointed their representatives, the nomination committee has held its first meeting. The nomination committee consists of the following members:

  • •      Bo Rydlinger, chairman of the nomination committee, background from banking and investments, appointed by a group of shareholders representing about 21 percent of shares and votes;
  • •      Daniel Johnsson, entrepreneur, business developer and investor, appointed by a group of shareholders representing about 24 percent of shares and votes;
  • •      Clas Sonesson, Chief Scientific Officer (CSO) at IRLAB and one of IRLAB’s founders. Appointed by a group of shareholders that consists of the company’s founders representing about 13 percent of shares and votes; and
  • •      Anders Vedin, chairman of the board of IRLAB Therapeutics AB.

Information about the nomination committee’s work and the instruction to the nomination committee can be found on the company website under the section for Corporate Governance. The nomination committee’s proposal will be presented in the summon to the annual general meeting 2020 and on the company’s web page – irlab.se.

Shareholders who wish to submit proposals to the nomination committee may contact the nomination committee at the company’s postal address or e-mail - info@irlab.se. In order to enable the nomination committee to take proposals into consideration they must be submitted in reasonable time prior to the annual general meeting and no later than January 31, 2020.

For further information

Bo Rydlinger, chairman of the nomination committee
Phone: +46 701 495 405                
E-mail: bo.rydlinger@sofama.se 

Anders Vedin, chairman of the board
Phone: +46 708 76 15 70
E-mail: anders.vedin@irlab.se

About IRLAB

IRLAB is a Swedish biotech company focused on Parkinson's disease. The company's clinical Phase II candidates, IRL752 and IRL790, intend to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (LIDs), psychosis and dementia. Through the proprietary ISP (Integrative Screening Process) research platform, IRLAB discovers and develops drug candidates for central nervous system (CNS) related diseases where big growing medical needs exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB's Certified Adviser on Nasdaq First North is FNCA Sweden AB, info@fnca.se, +46 (0)8‑528 00 399. More information on www.irlab.se.

Documents & Links